449 related articles for article (PubMed ID: 12673734)
1. Induction of intensive tumor suppression by antiangiogenic photodynamic therapy using polycation-modified liposomal photosensitizer.
Takeuchi Y; Kurohane K; Ichikawa K; Yonezawa S; Nango M; Oku N
Cancer; 2003 Apr; 97(8):2027-34. PubMed ID: 12673734
[TBL] [Abstract][Full Text] [Related]
2. Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome.
Takeuchi Y; Ichikawa K; Yonezawa S; Kurohane K; Koishi T; Nango M; Namba Y; Oku N
J Control Release; 2004 Jun; 97(2):231-40. PubMed ID: 15196750
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic photodynamic therapy with targeted liposomes.
Oku N; Ishii T
Methods Enzymol; 2009; 465():313-30. PubMed ID: 19913174
[TBL] [Abstract][Full Text] [Related]
4. Polycation liposome enhances the endocytic uptake of photosensitizer into cells in the presence of serum.
Takeuchi Y; Kurohane K; Ichikawa K; Yonezawa S; Ori H; Koishi T; Nango M; Oku N
Bioconjug Chem; 2003; 14(4):790-6. PubMed ID: 12862432
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
Ichikawa K; Hikita T; Maeda N; Yonezawa S; Takeuchi Y; Asai T; Namba Y; Oku N
Biochim Biophys Acta; 2005 May; 1669(1):69-74. PubMed ID: 15843001
[TBL] [Abstract][Full Text] [Related]
6. Photofrin-mediated photodynamic therapy induces vascular occlusion and apoptosis in a human sarcoma xenograft model.
Engbrecht BW; Menon C; Kachur AV; Hahn SM; Fraker DL
Cancer Res; 1999 Sep; 59(17):4334-42. PubMed ID: 10485481
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy targeted to tumor-induced angiogenic vessels.
Kurohane K; Tominaga A; Sato K; North JR; Namba Y; Oku N
Cancer Lett; 2001 Jun; 167(1):49-56. PubMed ID: 11323098
[TBL] [Abstract][Full Text] [Related]
8. Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth.
Ichikawa K; Takeuchi Y; Yonezawa S; Hikita T; Kurohane K; Namba Y; Oku N
Cancer Lett; 2004 Mar; 205(1):39-48. PubMed ID: 15036659
[TBL] [Abstract][Full Text] [Related]
9. Intensive tumor suppression by anti-angiogenic photodynamic therapy with polycation-modified liposomal photosensitizer.
Takeuchi Y; Kurohane K; Nango M; Oku N
Cell Mol Biol Lett; 2002; 7(2):301. PubMed ID: 12097971
[No Abstract] [Full Text] [Related]
10. Photodynamic synovectomy using benzoporphyrin derivative in an antigen-induced arthritis model for rheumatoid arthritis.
Trauner KB; Gandour-Edwards R; Bamberg M; Shortkroff S; Sledge C; Hasan T
Photochem Photobiol; 1998 Jan; 67(1):133-9. PubMed ID: 9477771
[TBL] [Abstract][Full Text] [Related]
11. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of photodynamic therapy using PAD-S31 and diode laser on human liver cancer cells.
Date M; Fukuchi K; Namiki Y; Okumura A; Morita S; Takahashi H; Ohura K
Liver Int; 2004 Apr; 24(2):142-8. PubMed ID: 15078479
[TBL] [Abstract][Full Text] [Related]
13. PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy.
Ichikawa K; Hikita T; Maeda N; Takeuchi Y; Namba Y; Oku N
Biol Pharm Bull; 2004 Mar; 27(3):443-4. PubMed ID: 14993821
[TBL] [Abstract][Full Text] [Related]
14. Foscan-based photodynamic treatment in vivo: correlation between efficacy and Foscan accumulation in tumor, plasma and leukocytes.
Maugain E; Sasnouski S; Zorin V; Merlin JL; Guillemin F; Bezdetnaya L
Oncol Rep; 2004 Sep; 12(3):639-45. PubMed ID: 15289849
[TBL] [Abstract][Full Text] [Related]
15. Application of long-circulating liposomes to cancer photodynamic therapy.
Oku N; Saito N; Namba Y; Tsukada H; Dolphin D; Okada S
Biol Pharm Bull; 1997 Jun; 20(6):670-3. PubMed ID: 9212988
[TBL] [Abstract][Full Text] [Related]
16. Selective depletion of a thymocyte subset in vitro with an immunomodulatory photosensitizer.
Jiang H; Granville DJ; McManus BM; Levy JG; Hunt DW
Clin Immunol; 1999 May; 91(2):178-87. PubMed ID: 10227810
[TBL] [Abstract][Full Text] [Related]
17. Skin necrosis due to photodynamic action of benzoporphyrin depends on circulating rather than tissue drug levels: implications for control of photodynamic therapy.
Lin GC; Tsoukas ML; Lee MS; González S; Vibhagool C; Anderson RR; Kollias N
Photochem Photobiol; 1998 Oct; 68(4):575-83. PubMed ID: 9796441
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy for human oral squamous cell carcinoma and xenografts using a new photosensitizer, PAD-S31.
Date M; Sakata I; Fukuchi K; Ohura K; Azuma Y; Shinohara M; Matsuzaki K; Namiki Y; Takahashi H
Lasers Surg Med; 2003; 33(1):57-63. PubMed ID: 12866122
[TBL] [Abstract][Full Text] [Related]
19. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
20. Photodynamic therapy for cutaneous proliferative vascular tumors in a mouse model.
Middelkamp-Hup MA; Sánchez-Carpintero I; Kossodo S; Waterman P; González S; Mihm MC; Anderson RR
J Invest Dermatol; 2003 Sep; 121(3):634-9. PubMed ID: 12925226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
